Related Experiment Video

Updated: Nov 11, 2025

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.0K

Two Tales of Cardiomyopathy: Underscore for One Health Initiative

Imaobong Chinedozi1, Joseph Zarin2, Rebecca Quinn2

  • 1Tufts Medical Center, Department of Anesthesiology and Perioperative Medicine, Boston, MA.

Journal of Cardiothoracic and Vascular Anesthesia
|March 30, 2021
PubMed

Insights

Hypertrophic cardiomyopathy, a genetic heart condition, can cause sudden cardiac death. Further research and collaboration are needed to fully understand and manage this complex disease.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a primary cause of sudden cardiac death.
  • Mutations in cardiac sarcomere genes are implicated in HCM pathogenesis.
  • Despite extensive research, the full scope of HCM remains incompletely understood.

Purpose of the Study:

  • To present two clinical cases of hypertrophic cardiomyopathy.
  • To emphasize the necessity of multidisciplinary collaboration in managing HCM.
  • To align with the principles of the One Health Initiative for comprehensive disease management.

Main Methods:

  • Case study review of two patients with hypertrophic cardiomyopathy.
  • Literature review on genetic mutations and sarcomere function in HCM.
  • Analysis of collaborative care models in cardiovascular disease management.

Main Results:

  • The presented cases illustrate the clinical variability and challenges in diagnosing and treating HCM.
  • Highlighting the importance of integrating genetic, clinical, and research perspectives.
  • Underscoring the potential of the One Health approach to address complex cardiomyopathies.

Conclusions:

  • Hypertrophic cardiomyopathy requires a multifaceted understanding due to its genetic basis and clinical impact.
  • Multidisciplinary collaboration, as advocated by the One Health Initiative, is crucial for advancing HCM research and patient care.
  • Continued investigation into sarcomere biology and integrated healthcare strategies is essential for improving outcomes in sudden cardiac death prevention.

Keywords:
One HealthOne Health Initiativecardiomyopathyechocardiographyhypertrophic cardiomyopathy

More Related Videos

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.1K
Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

10.6K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
106
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
129
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
190
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
124
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
172
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
122